Top

Published in:

01-04-2015

Aspirin in secondary prevention of recurrent venous thromboembolism

Authors: Kochawan Boonyawat, Mark A. Crowther

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2015

Excerpt

Aspirin is well established in its efficacy for secondary prevention of arterial thrombosis [1]. In venous thrombosis, however, Several early studies failed to demonstrate a beneficial effect during aspirin use for the prevention of venous thromboembolism (VTE). However these early studies were, in general, small and thus may have lacked power to detect the efficacy of aspirin for the prevention of VTE. …

Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P et al (2012) Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e637S–e668SPubMedCentralPubMed

Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy–III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 308(6923):235–246CrossRef

Pulmonary Embolism Prevention (PEP) trial Collaborative Group (2000) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355(9212):1295–1302CrossRef

Undas A, Brummel-Ziedins K, Mann KG (2014) Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid. J Thrombo Haemost 12(11):1776–1787CrossRef

Steele P (1980) Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet 2(8208–8209):1328–1329CrossRefPubMed

Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M et al (2012) Aspirin for preventing the recurrence of venous thromboembolism. New Engl J Med 366(21):1959–1967CrossRefPubMed

Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P et al (2012) Low-dose aspirin for preventing recurrent venous thromboembolism. New Engl J Med 367(21):1979–1987CrossRefPubMed

Simes J, Becattini C, Agnelli G, Eikelboom JW, Kirby AC, Mister R et al (2014) Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 130(13):1062–1071CrossRefPubMed

Milan M, Noventa F, Ghirarduzzi A, Pengo V, Vedovetto V, Filippi L et al (2012) Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study. J Thrombo Haemost 10(10):2205–2206CrossRef

10.

Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, The Duration of Anticoagulation Trial Study Group et al (1997) The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. New Engl J Med 336(6):393–398CrossRefPubMed

11.

Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR et al (1999) A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. New Engl J Med 340(12):901–907CrossRefPubMed

12.

Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Warfarin Optimal Duration Italian Trial Investigators et al (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. New Engl J Med 345(3):165–169CrossRefPubMed

13.

Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M et al (2003) Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 139(1):19–25CrossRefPubMed

14.

Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P (2007) The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 147(11):766–774CrossRefPubMed

15.

Kahn SR, Shbaklo H, Lamping DL, Holcroft CA, Shrier I, Miron MJ et al (2008) Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost 6(7):1105–1112CrossRefPubMed

16.

Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA et al (2014) The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the american heart association. Circulation 130(18):1636–1661CrossRefPubMed

17.

Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D et al (2009) Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 150(9):577–585CrossRefPubMed

18.

Siragusa S, Malato A, Anastasio R, Cigna V, Milio G, Amato C et al (2008) Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the duration of anticoagulation based on compression ultrasonography (DACUS) study. Blood 112(3):511–515CrossRefPubMed

19.

Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T et al (2008) Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 149(7):481–490 W94CrossRefPubMed

20.

Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S et al (2010) Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood 115(3):481–488CrossRefPubMed

21.

Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med 363(26):2499–2510CrossRef

22.

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al (2013) Apixaban for extended treatment of venous thromboembolism. New Engl J Med 368(8):699–708CrossRefPubMed

23.

Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D et al (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New Engl J Med 368(8):709–718CrossRefPubMed

24.

Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e494SPubMedCentralPubMed

Title: Aspirin in secondary prevention of recurrent venous thromboembolism
Authors: Kochawan Boonyawat
Mark A. Crowther
Publication date: 01-04-2015
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 3/2015
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-015-1196-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2015

Role of thrombophilia testing: con

Regulatory, legislative, and policy updates with anticoagulant use

Practical aspects of treatment with target specific anticoagulants: initiation, payment and current market, transitions, and venous thromboembolism treatment

Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review

Proceedings of the 13th National Conference on Anticoagulant Therapy

Clinical significance and management of subsegmental pulmonary embolism

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials